Press Releases

GelStat Announces the First of Its Cross Media Advertising Strategy With a Full Page Ad in Woman's Day Magazine to Be Distributed in August

Download PDF

MINNEAPOLIS, MN -- (MARKETWIRE) -- 07/18/07 -- GelStat Corporation (PINKSHEETS: GSAC), a consumer healthcare company primarily focused on the development and marketing of over-the-counter (OTC) products for the safe and effective treatment of pain and inflammation, is pleased to announce its Migraine product will be featured in a full page advertisement ( in the September issue of Woman's Day magazine to be distributed in August. The ad will target 250,000 readers in the Northeastern Region of the United States and introduce Gelstat Migraine to women between the ages of 15 and 65.

James LaFlamme, the Chairman of the Board Directors of GelStat Corp., stated that, "US Marketing, Ltd. has continually focused our products on the core of our markets. It is this singular focus that is assisting us in re-building the foundation of our Company."

Tom DeSantis, GelStat's independent business development manager, said that, "We are pleased with the strong growth in sales and positive feed back that we are getting from our recent marketing efforts. The full page print ad in Woman's Day will further strengthen our new cross media advertising strategy, combining print, cable, and the Internet, targeting the Northeast Region of the United States and branding the products of the Company to the right audience."


GelStat Corporation is dedicated to providing safe and effective over-the-counter (OTC) treatments for pain and inflammation.

GelStat Migraine is a sublingually (under the tongue) administered OTC medication for acute relief from the pain and associated symptoms of migraine. Over 90 percent of the 30 million Americans with migraine use OTC headache remedies, generally aspirin or other non-steroidal anti-inflammatory drugs. Americans spend $2.6 billion each year on 600 million units of such products, although they are believed to be effective for only about 25 percent of those with moderate to severe migraine.

Click the following links to view supporting information on the effectiveness of GelStat Migraine:

Open Label Clinical Study performed by Dr. Rodger Cady and Dr, Curtis Schreiber of the Headache Care Center in Springfield, Missouri

Double-Blind Placebo Controlled study performed by Dr. Shenna Aurora co-director of the Swedish Headache Center in Seattle Washington

2 Minute Video Demonstrating the Product and its Successful Treatment of a Migraine Headache

The Company also has a suite of additional, effective healthcare products that address large consumer markets. GelStat(TM) Arthritis is the second available product to utilize GelStat's patent pending formulation. It is provided as a daily use, sublingual dissolving tablet. Arthritis and chronic joint symptoms are among the most common medical complaints in the United States. The Center for Disease Control estimates that, in its many forms, arthritis affects up to 70 million Americans, causing significant, often long-term pain and disability. Typical arthritis medications often provide only marginal relief, and are increasingly associated with frequent and significant side effects such as gastrointestinal bleeding, stroke, heart attack and potentially life-threatening skin reactions.

The Company has also developed "GelStat(TM) Sinus" and "GelStat(TM) Sleep," and believes that each of these products performs well and is effective for its intended use. The National Institute of Allergy and Infectious Disease estimates that 37 million Americans are affected by sinusitis every year, with at least 20 million more suffering from allergies. Approximately 70 million Americans are reported to be "problem sleepers."

For more information, visit

Safe Harbor Statement Under the Private Securities Litigation Act of 1995

With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of GelStat could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rate and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors, please review our SEC filings.

For more information contact:

Redwood Consultants, LLC